Search

Your search keyword '"Reveille, John D."' showing total 1,524 results
Start Over Author "Reveille, John D."
1,524 results on '"Reveille, John D."'

205. Predictors of Hand Contracture in Early SSc and the Effect on Hand Function: A Prospective Study of the GENISOS Cohort

Author

Buni, Maryam, Joseph, Joyce, Pedroza, Claudia, Theodore, Sam, Nair, Deepthi, McNearney, Terry A., Draeger, Hilda T., Reveille, John D., Assassi, Shervin, and Mayes, Maureen D.

Subjects
Adult, Male, Contracture, Scleroderma, Systemic, Middle Aged, Hand, Prognosis, Severity of Illness Index, Article, Risk Factors, Disease Progression, Humans, Female, Prospective Studies
Abstract

To identify baseline features that predict progression of hand contractures and to assess the effect of contractures on functional status in the prospective GENISOS cohort.Rate of decline in hand extension, as an indicator of hand contracture, was the primary outcome. We assessed longitudinal hand extension measurements, modified Health Assessment Questionnaire (MHAQ) score, Medical Outcomes Study Short Form-36 (SF-36) physical function score, and demographic, clinical, and serological variables. Subjects with ≥ 2 hand measurements at least 6 months apart were included.A total of 1087 hand measurements for 219 patients were available over an average of 8.1 ± 4.8 years. Hand extension decreased on average by 0.11 cm/year. Antitopoisomerase I antibody (ATA) positivity and higher modified Rodnan Skin Score (mRSS) were predictive of faster decline in hand extension (p = 0.009 and p = 0.046, respectively). In a subgroup analysis of 62 patients with ≤ 2 years from SSc onset, ATA and diffuse disease type were associated with faster decline in hand extension; anticentromere positivity was associated with slower rate of decline. Although the rate of decline in patients with disease duration ≤ 2 years was numerically higher, the difference was not statistically significant. Hand extension continued to decline in a linear fashion over time and was inversely related to overall functional status.ATA was predictive of contracture development in both early disease (≤ 2 yrs) and in the overall cohort. Hand extension declined linearly over time and was inversely associated with MHAQ and SF-36 scores. ATA positivity and higher baseline mRSS were predictive of faster decline in hand extension.

Published
2019

219. HLA Polymorphisms in African Americans with Idiopathic Inflammatory Myopathy: Allelic Profiles Distinguish Patients with Different Clinical Phenotypes and Myositis Autoantibodies

Author

OʼHanlon, Terrance P., Rider, Lisa G., Mamyrova, Gulnara, Targoff, Ira N., Arnett, Frank C., Reveille, John D., Carrington, Mary, Gao, Xiaojiang, Oddis, Chester V., Morel, Penelope A., Malley, James D., Malley, Karen, Shamim, Ejaz A., Chanock, Stephen J., Foster, Charles B., Bunch, Thomas, Reed, Ann M., Love, Lori A., and Miller, Frederick W.

Published
2006

234. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and-DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies

Author

O'Hanlon, Terranace P., Carrick, Danielle Mercatante, Targoff, Ira N., Arnett, Frank C., Reveille, John D., Carrington, Mary, Gao, Xiaojiang, Oddis, Chester V., Morel, Penelope A., Malley, James D., Malley, Karen, Shamin, Ejaz A., Rider, Lisa G., Chanock, Stephen J., Foster, Chales B., Thomas, Bunch, Blackshear, Perry L., Plotz, Paul H., Love, Lori A., and Miller, Frederick W.

Subjects
Muscle diseases -- Genetic aspects, Muscle diseases -- Risk factors, Autoimmune diseases -- Genetic aspects, Autoimmune diseases -- Risk factors
Published
2006

236. A Locus On Chromosome 9p Predisposes to a Specific Disease Manifestation, Acute Anterior Uveitis, in Ankylosing Spondylitis, a Genetically Complex, Multisystem, Inflammatory Disease

Author

Martin, Tammy M., Zhang, Ge, Luo, Jingchun, Jin, Li, Doyle, Trudy M., Rajska, Barbara M., Coffman, Jessica E., Smith, Justine R., Becker, Matthias D., Mackensen, Friederike, Khan, Muhammad A., Levinson, Ralph D., Schumacher, H. Ralph, Wade, N. Kevin, Rosenbaum, James T., and Reveille, John D.

Published
2005

237. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo–Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Author

Deodhar, Atul, Poddubnyy, Deni, Pacheco-Tena, Cesar, Salvarani, Carlo, Lespessailles, Eric, Rahman, Proton, Järvinen, Pentti, Sanchez-Burson, Juan, Gaffney, Karl, Lee, Eun Bong, Krishnan, Eswar, Santisteban, Silvia, Li, Xiaoqi, Zhao, Fangyi, Carlier, Hilde, Reveille, John D., Antolini, Christopher, Azevedo, Valderilio, Barkham, Magnu, Rodriguez, Aaron Alejandro Barrera, Berman, Alberto, Blicharski, Tomasz, Brzezicki, Jan, Burmester, Gerd, Carrio, Judith, Collantes, Eduardo, Combe, Bernard, Cons-Molina, Fidencio, Cortes-Maisonet, Gregorio, Dudek, Anna, Barragan, Sergio Duran, Elkayam, Ori, Flint, Kathleen, Galeazzi, Mauro, Gaylis, Norman, Goddard, David, Fernandez, Carlos Gonzalez, Goupille, Philippe, Masmitja, Jordi Grataco, Greenwald, Maria, Gremese, Elisa, Hong, Seung Jae, Howell, Mary, Hrycaj, Pawel, Ince, Akgun, Ju, Ji Hyeon, Kaine, Jeffrey, Kang, Seong Wook, Keiserman, Mauro, Kim, Tae-Hwan, Kivitz, Alan, Klein, Steven, Kremer, Joel, Lee, Sang Heon, Lee, Chang Keun, Lee, Sang-Hoon, Lidman, Roger, Loveless, Jame, Lucero, Eleonora, Cocco, Jose Maldonado, Marcolino, Flora, Mariette, Xavier, Mehta, Daksha, Morin, Frederic, Moscovici, Yolanda, Mueller, Eric, Mysler, Eduardo, Blasco, Francisco Navarro, Nguyen, Minh, Pantojas, Carlo, Park, Min-Chan, Jesus, Amarilis Perez-De, Peters, Eric, Plebanski, Rafal, Querubin, Roel, Remus, Cesar Ramo, Reitblat, Tatiana, Rivera, Tania, Rodriguez, Juan Cruz Rizo, Sayers, Michael, Scotton, Antonio, Scoville, Craig, Shaw, David, Shin, Kichul, Singhal, Atul, Skinner, Cassandra, Soto-Raices, Oscar, Soubrier, Martin, Szymanska, Malgorzata, Thai, Christine, van de Sande, Marleen, Wells, Alvin, Wojciechowski, Rafal, Xavier, Ricardo, Ximenes, Antonio, Zisman, Devy, Gremese, Elisa (ORCID:0000-0002-2248-1058), Deodhar, Atul, Poddubnyy, Deni, Pacheco-Tena, Cesar, Salvarani, Carlo, Lespessailles, Eric, Rahman, Proton, Järvinen, Pentti, Sanchez-Burson, Juan, Gaffney, Karl, Lee, Eun Bong, Krishnan, Eswar, Santisteban, Silvia, Li, Xiaoqi, Zhao, Fangyi, Carlier, Hilde, Reveille, John D., Antolini, Christopher, Azevedo, Valderilio, Barkham, Magnu, Rodriguez, Aaron Alejandro Barrera, Berman, Alberto, Blicharski, Tomasz, Brzezicki, Jan, Burmester, Gerd, Carrio, Judith, Collantes, Eduardo, Combe, Bernard, Cons-Molina, Fidencio, Cortes-Maisonet, Gregorio, Dudek, Anna, Barragan, Sergio Duran, Elkayam, Ori, Flint, Kathleen, Galeazzi, Mauro, Gaylis, Norman, Goddard, David, Fernandez, Carlos Gonzalez, Goupille, Philippe, Masmitja, Jordi Grataco, Greenwald, Maria, Gremese, Elisa, Hong, Seung Jae, Howell, Mary, Hrycaj, Pawel, Ince, Akgun, Ju, Ji Hyeon, Kaine, Jeffrey, Kang, Seong Wook, Keiserman, Mauro, Kim, Tae-Hwan, Kivitz, Alan, Klein, Steven, Kremer, Joel, Lee, Sang Heon, Lee, Chang Keun, Lee, Sang-Hoon, Lidman, Roger, Loveless, Jame, Lucero, Eleonora, Cocco, Jose Maldonado, Marcolino, Flora, Mariette, Xavier, Mehta, Daksha, Morin, Frederic, Moscovici, Yolanda, Mueller, Eric, Mysler, Eduardo, Blasco, Francisco Navarro, Nguyen, Minh, Pantojas, Carlo, Park, Min-Chan, Jesus, Amarilis Perez-De, Peters, Eric, Plebanski, Rafal, Querubin, Roel, Remus, Cesar Ramo, Reitblat, Tatiana, Rivera, Tania, Rodriguez, Juan Cruz Rizo, Sayers, Michael, Scotton, Antonio, Scoville, Craig, Shaw, David, Shin, Kichul, Singhal, Atul, Skinner, Cassandra, Soto-Raices, Oscar, Soubrier, Martin, Szymanska, Malgorzata, Thai, Christine, van de Sande, Marleen, Wells, Alvin, Wojciechowski, Rafal, Xavier, Ricardo, Ximenes, Antonio, Zisman, Devy, and Gremese, Elisa (ORCID:0000-0002-2248-1058)

Abstract

Objective: To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi). Methods: In this phase III randomized, double-blind, placebo-controlled trial, adult patients with an inadequate response to or intolerance of 1 or 2 TNFi and an established diagnosis of axial SpA (according to the Assessment of SpondyloArthritis international Society [ASAS] criteria for radiographic axial SpA, with radiographic sacroiliitis defined according to the modified New York criteria and ≥1 feature of SpA) were recruited and randomized 1:1:1 to receive placebo or 80-mg subcutaneous ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W), with an 80-mg or 160-mg starting dose. The primary end point was 40% improvement in disease activity according to the ASAS criteria (ASAS40) at week 16. Secondary outcomes and safety were also assessed. Results: A total of 316 patients were randomized to receive placebo (n = 104), IXEQ2W (n = 98), or IXEQ4W (n = 114). At week 16, significantly higher proportions of IXEQ2W patients (n = 30 [30.6%]; P = 0.003) or IXEQ4W patients (n = 29 [25.4%]; P = 0.017) had achieved an ASAS40 response versus the placebo group (n = 13 [12.5%]), with statistically significant differences reported as early as week 1 with ixekizumab treatment. Statistically significant improvements in disease activity, function, quality of life, and spinal magnetic resonance imaging–evident inflammation were observed after 16 weeks of ixekizumab treatment versus placebo. Treatment-emergent adverse events (AEs) with ixekizumab treatment were more frequent than with placebo. Serious AEs were similar across treatment arms. One death was reported (IXEQ2W group). Conclusion: Ixekizumab treatment for 16 weeks in patients with active radiographic axial SpA and previous inadequate response to or intolerance of 1 or 2 TNFi yields rapid and signi

Published
2019

239. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and-DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians

Author

O'Hanlon, Terrance P., Carrick, Danielle Mercatante, Arnett, Frank C., Reveille, John D., Carrington, Mary, Gao, Xiaojang, Oddis, Chester V., Morel, Penelope A., Malley, James D., Malley, Karen, Dreyfuss, Jonathan, Shamim, Ejaz A., Rider, Lisa G., Chanock, Stephen J., Foster, Charles B., Bunch, Thomas, Plotz, Paul H., Love, Lori A., and Miller, Frederick W.

Subjects
Muscle diseases -- Genetic aspects, Muscle diseases -- Causes of, Whites -- Health aspects, Autoimmune diseases -- Causes of, Autoimmune diseases -- Genetic aspects
Published
2005

242. Lack of linkage of IL1RN genotypes with ankylosing spondylitis susceptibility

Author

Jin, Li, Zhang, Ge, Akey, Joshua M., Luo, Jingchun, Lee, Juwon, Weisman, Michael H., Bruckel, Jane, Inman, Robert D., Stone, Millicent A., Khan, Muhammad A., Schumacher, H. Ralph, Maksymowych, Walter P., Mahowald, Maren L., Sawitzke, Allen D., Vasey, Frank B., Yu, David T. Y., and Reveille, John D.

Published
2004

243. Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis

Author

Assassi, Shervin, Mayes, Maureen D., McNearney, Terry, Fischbach, Michael, Reveille, John D., Arnett, Frank C., and Tan, Filemon K.

Subjects
Nitric oxide -- Physiological aspects, Nitric oxide -- Research, Genetic polymorphisms -- Research, Genetic polymorphisms -- Physiological aspects, Scleroderma (Disease) -- Research, Scleroderma (Disease) -- Genetic aspects, Systemic scleroderma -- Research, Systemic scleroderma -- Genetic aspects, Health, Health care industry
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2005.01.055 Byline: Shervin Assassi (a), Maureen D. Mayes (a), Terry McNearney (b), Michael Fischbach (c), John D. Reveille (a), Frank C. Arnett (a), Filemon K. Tan (a) Author Affiliation: (a) Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston (b) Division of Rheumatology, University of Texas Medical Branch (c) Division of Rheumatology, University of Texas Health Science Center at San Antonio Article Note: (footnote) Supported by NIAMS Specialized Center of Research (SCOR) in scleroderma grant (P50AR4448) and University Clinical Research Center grants M01-RR02558 (UTH-HSC), M01-RR00073 (UTMB), M01-RR01346 (UT-SA).

Published
2005

245. Genetic Studies in Familial Ankylosing Spondylitis Susceptibility

Author

Zhang, Ge, Luo, Jingchun, Bruckel, Jane, Weisman, Michael A., Schumacher, H. Ralph, Khan, Muhammad A., Inman, Robert D., Mahowald, Maren, Maksymowych, Walter P., Martin, Tammy M., Yu, David T. Y., Stone, Millicent, Rosenbaum, James T., Newman, Patricia, Lee, Juwon, McClain, Jo A., West, O. Clark, Jin, Li, and Reveille, John D.

Published
2004

246. Spondyloarthritis: update on pathogenesis and management

Author

Reveille, John D. and Arnett, Frank C.

Subjects
Spondyloarthropathies -- Care and treatment, Spondyloarthropathies -- Development and progression, Spondyloarthropathies -- Causes of, Spondyloarthropathies -- Genetic aspects, Spondyloarthropathies -- Research, Health, Health care industry
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2005.01.001 Byline: John D. Reveille, Frank C. Arnett Abstract: A great deal of progress has occurred in the past few years in elucidating the causes and designing new treatments for ankylosing spondylitis and other types of spondyloarthritis. In addition to the human leukocyte antigen (HLA)-B27 and other major histocompatibility complex (MHC) genes, chromosomal regions and genes elsewhere in the genome are being implicated both in disease susceptibility and severity. The various ways HLA-B27 may function in causing spondyloarthritis now are better understood to encompass not only antigen presentation but also other mechanisms, possibly all being operative in pathogenesis (misfolding of the HLA-B27 molecule, impaired intracellular killing of bacteria, and HLA-B27 itself serving as an autoantigen). Specific enteric and sexually acquired infections can trigger reactive arthritis, though no specific microbe has been identified in other forms of spondyloarthritis. Intestinal inflammation with impairment of the gut:blood barrier may be operative in driving ankylosing spondylitis and enteropathic arthritis. A number of treatments have been tried in spondyloarthritis, including older agents such as methotrexate and sulfasalazine but also newer drugs such as pamindronate. The recent introduction of tumor necrosis factor (TNF) blockers in the treatment of spondyloarthritis has offered the most hope in not only relieving symptoms and signs of both peripheral arthritis and enthesitis but also spinal disease, which often has been refractory to other agents. Their high cost and considerable side effect profile, however, have necessitated the establishment of guidelines for their use in these diseases in order to target the patient in whom they are likely to have the most benefit. Author Affiliation: Division of Rheumatology, Department of Internal Medicine, The University of Texas-Houston Health Science Center

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results